Vaishali Pharma Fair Value
Vaishali Pharma (VAISHALI) average fair value is ₹20.98 across 6 valuation models — P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF), vs a current market price of ₹7.71 (+172.16%), fair value range ₹0.38–₹81.62. For live price and a broader fundamental view, visit VAISHALI share price.
Fair Value Analysis Export
VAISHALI Fair Value vs Current Price — Valuation Summary
VAISHALI average fair value, fair value range, price gap and valuation status across 6 models: P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF). Explore VAISHALI value investing to estimate fundamental worth using multiple valuation models.
P/E Based Valuation
P/B Based Valuation
Price-to-Sales Valuation
Asset-Based Valuation
Benjamin Graham Number
Discounted Cash Flow (DCF)
VAISHALI Fair Value Analysis — Data Sources & Coverage
Vaishali Pharma financial data sources, valuation methods applied and sector benchmarks used — 2025 financial year. Examine VAISHALI quarterly results for recent quarterly revenue, profit and EPS trends.
Available Data Sources: Financial statements, balance sheet data , sector comparisons.
Data Currency: Financial data is from the previous year (2025).
VAISHALI vs Healthcare Sector Peers — P/E, P/B & Market Cap
Vaishali Pharma P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Par Drugs & Chemical | PAR | - | 1.21 | ₹132 |
| Sat Kartar Shopping | SATKARTAR | 29.05 | 5.53 | ₹307 |
| Acutaas Chemicals | ACUTAAS | 67.94 | 13.69 | ₹19,597 |
| Jeena Sikho Lifecare | JSLL | 40.04 | 22.87 | ₹8,290 |
| Murae Organisor | MURAE | 2.86 | 0.2 | ₹41 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.